pSivida names Nancy Lurker as president, CEO and board member
From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, where she oversaw a multi-billion-dollar product portfolio covering cardiovascular, bone, pain, urology, respiratory, dermatology, biologics, neurology and metabolic therapeutic areas.
From 2003 to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company, now part of IMS Health Holdings, Inc..
From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation, where she led a global business unit that commercialized urology, cardiovascular, central nervous system, respiratory and women’s health drugs, overseeing the worldwide launch of Detrol and Detrol LA and repositioning Ambien for revenue growth.
She also served as a member of Pharmacia’s U.S. executive management committee.
Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. She serves as a member of the Board of Directors of the privately held Cancer Treatment Centers of America.
Ms. Lurker previously served as a member of the Boards of Directors of Mallinckrodt Pharmaceuticals and Auxilium Pharmaceuticals.
She received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. ■
LATEST MOVES FROM Massachusetts
- DentaQuest appoints Alison Corcoran as CMO
- RXI Pharma names Gerrit Dispersyn chief development officer
- resTORbio appoints Joan Mannick as CMO
- C&W Services appoints Mike Losier as director
- Charles River Associates appoints Robert A. Whitman to board
More inside POST